Peptide Receptor Radionuclide Therapy (Lu-177 DOTATATE) in Progressive Neuroendocrine Tumors (NETs): Potential Predictors of Progression Free Survival (PFS)

被引：0
|
作者：
Badawy, Mohmed [1 ]
Johnson, Geoffrey B. [1 ]
Hobday, Timothy [1 ]
Packard, Annie T. [1 ]
Jain, Manoj [2 ]
Halfdanarson, Thorvardur R. [1 ]
Young, Jason R. [1 ]
Thorpe, Matthew P. [1 ]
Eiring, Rachel A. [1 ]
Kendi, Ayse Tuba [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin, Jacksonville, FL 32224 USA
来源：
PANCREAS | 2022年 / 51卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
C-24
引用
收藏
页码：E42 / E42
页数：1
相关论文
共 50 条
  • [31] Hematological Markers as Predictors of Treatment Outcomes with Lu-177 DOTATATE in Patients with Advanced Neuroendocrine Tumors
    Satapathy, Swayamjeet
    Bhattacharya, Anish
    Sood, Ashwani
    Kapoor, Rakesh
    Gupta, Rajesh
    Sood, Apurva
    Sharma, Prashant
    Khosla, Divya
    Mittal, Bhagwant Rai
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2022, 37 (01) : 23 - 29
  • [32] Evaluation of Kidney Dose in Neuroendocrine Tumors Patients after Peptide Receptor Radionuclide Therapy using 177Lu-DOTATATE
    Hidayati, N. R.
    Poon, A.
    Willowson, K.
    Eslick, E.
    Ryu, H.
    Bailey, D. L.
    ATOM INDONESIA, 2019, 45 (03) : 147 - 152
  • [33] Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE
    Pretot, Dominique
    Engel-Bicik, Ivette
    Kenkel, David
    Kaufmann, Philipp A.
    Treyer, Valerie
    Siebenhuner, Alexander R.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (03) : 1204 - 1217
  • [34] 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors: Review of Treatment Workflow and Challenging Clinical Scenarios
    Abiodun-Ojo, Olayinka
    Shin, Muheon
    Chopra, Jigyasa
    Muzahir, Saima
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [35] Data collection procedures for bone marrow dosimetry in peptide receptor radionuclide therapy with 177Lu-DOTATATE on neuroendocrine tumors
    Frederiksen, M. H. B.
    Klausen, T. L.
    de Nijs, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S631 - S631
  • [36] Outcome of Peptide Receptor Radionuclide Treatment with Lu-177 DOTATATE from Ankara University.
    Soydal, C.
    Peker, A.
    Ozkan, E.
    Kucuk, O. N.
    Kir, M. K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S532 - S532
  • [37] Neuroendocrine peritoneal disease and [177Lu]DOTATATE peptide receptor radionuclide therapy: a therapeutic challenge with potential clinical complications
    Poterszman, Nathan
    Baltzinger, Philippe
    Bessac, Darejan Mamulashvili
    Van, Floriane Pham
    Goichot, Bernard
    Mertz, Luc
    Addeo, Pietro
    Brigand, Cecile
    Imperiale, Alessio
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2025,
  • [38] Cardiac Metastases of Neuroendocrine Tumors Treated With 177Lu DOTATATE Peptide Receptor Radionuclide Therapy or 131I-MIBG Therapy
    Makis, William
    McCann, Karey
    Bryanton, Mark
    McEwan, Alexander J. B.
    CLINICAL NUCLEAR MEDICINE, 2015, 40 (12) : 962 - 964
  • [39] Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
    Levart, D.
    Kalogianni, E.
    Corcoran, B.
    Mulholland, N.
    Vivian, G.
    EJNMMI PHYSICS, 2019, 6 (1)
  • [40] Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
    D. Levart
    E. Kalogianni
    B. Corcoran
    N. Mulholland
    G. Vivian
    EJNMMI Physics, 6
12345